Answers are grounded in this paper and cite their sources.
Guideline comparison reveals differing perspectives on fatty liver disease management in Europe and Asia, indicating regional health priorities.
Introduction Metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) represent an increasing global health challenge for modern medicine. Europe and Asia have responded with region-specific guidelines -respectively, European Association for the Study of the Liver (EASL)-European Association for the Study of Diabetes (EASD)-European Association for the Study of Obesity (EASO) for MASLD and Asian Pacific Association for the Study of the Liver (APASL) for MAFLD- that reflect different epidemiology, clinical priorities and healthcare systems.
No takes yet. Share an insight, caveat, or question.
Ludovico Abenavoli (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: